TRex Bio

News

Bambusa, Aspen, and Tang added to IPO pipeline

2026's sizeable haul of IPOs shows no signs of letting up, with three more biotechs – Bambusa, Aspen, and blank cheque firm Tang – joining the queue.

News

ADARx, Trex, and Retension take aim at IPOs

The appetite among biotechs for IPOs shows no signs of being satisfied, with three more – ADARx, TRex, and Retension – making their intentions known.

News

Metsera gets $215m for obesity trials, and other financings

If any further evidence were needed for the insatiable investor appetite for companies with obesity assets, look no further than New York start-up Metsera.

Bambusa, Aspen, and Tang added to IPO pipeline

ADARx, Trex, and Retension take aim at IPOs

Metsera gets $215m for obesity trials, and other financings

AZ seeking $1.5bn in savings by end-2029

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks